Bay Area's Arcus Biosciences Scores $107M, Initiates Two Clinical Trials Post author:Sam Post published:November 12, 2017 Post category:BioPharma Now totaling $227M, Arcus Biosciences announced it had closed a $107M Series C financing. Source: BioSpace You Might Also Like Vertex Quietly Terminates a Small Phase II CF Trial September 11, 2017 Finally! STADA Arzneimittel Accepts $5.6 Billion Takeover Offer From Cinven April 9, 2017 Double Duty: FDA Head in the Running to Lead the After Flightgate Scandal October 2, 2017